CA2106249C - Solution pour la perfusion, la conservation et la reperfusion d'organes - Google Patents

Solution pour la perfusion, la conservation et la reperfusion d'organes Download PDF

Info

Publication number: CA2106249C
Authority: CA; Canada
Prior art keywords: glutathione; reduced; solution; solution according; air
Prior art date: 1992-09-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002106249A

Other languages

English (en)

French (fr)

Other versions

CA2106249A1 (fr

Inventor

Philippe Menasche

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Imtix Sangstat

Original Assignee

Imtix Sangstat

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-09-18

Filing date

1993-09-15

Publication date

2009-04-14

1993-09-15 Application filed by Imtix Sangstat filed Critical Imtix Sangstat

1994-03-19 Publication of CA2106249A1 publication Critical patent/CA2106249A1/fr

2009-04-14 Application granted granted Critical

2009-04-14 Publication of CA2106249C publication Critical patent/CA2106249C/fr

2013-09-15 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

230000010410 reperfusion Effects 0.000 title claims abstract description 18
210000000056 organ Anatomy 0.000 title abstract description 16
238000004321 preservation Methods 0.000 title abstract description 8
230000010412 perfusion Effects 0.000 title abstract description 5
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 76
108010024636 Glutathione Proteins 0.000 claims abstract description 29
229960003180 glutathione Drugs 0.000 claims abstract description 29
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 21
239000001301 oxygen Substances 0.000 claims abstract description 21
229910052760 oxygen Inorganic materials 0.000 claims abstract description 21
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 12
238000003860 storage Methods 0.000 claims abstract description 12
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 8
229930195725 Mannitol Natural products 0.000 claims abstract description 8
239000011575 calcium Substances 0.000 claims abstract description 8
239000000594 mannitol Substances 0.000 claims abstract description 8
235000010355 mannitol Nutrition 0.000 claims abstract description 8
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 7
229930195712 glutamate Natural products 0.000 claims abstract description 7
229940099584 lactobionate Drugs 0.000 claims abstract description 7
JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 claims abstract description 7
239000000203 mixture Substances 0.000 claims abstract description 7
239000002253 acid Substances 0.000 claims abstract description 6
239000011777 magnesium Substances 0.000 claims abstract description 5
239000001110 calcium chloride Substances 0.000 claims abstract description 4
229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 4
239000000470 constituent Substances 0.000 claims abstract description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims abstract description 4
229910001629 magnesium chloride Inorganic materials 0.000 claims abstract description 4
239000001103 potassium chloride Substances 0.000 claims abstract description 4
WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 4
235000011164 potassium chloride Nutrition 0.000 claims abstract description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
150000003841 chloride salts Chemical class 0.000 claims abstract description 3
XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims abstract 2
239000000243 solution Substances 0.000 claims description 66
238000002360 preparation method Methods 0.000 claims description 14
238000001802 infusion Methods 0.000 claims description 8
150000001875 compounds Chemical class 0.000 claims description 7
239000004033 plastic Substances 0.000 claims description 4
229920003023 plastic Polymers 0.000 claims description 4
UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims description 3
150000001450 anions Chemical class 0.000 claims description 3
230000015572 biosynthetic process Effects 0.000 claims description 3
229960000958 deferoxamine Drugs 0.000 claims description 3
150000001768 cations Chemical class 0.000 claims description 2
239000002738 chelating agent Substances 0.000 claims description 2
238000002347 injection Methods 0.000 claims description 2
239000007924 injection Substances 0.000 claims description 2
229910052751 metal Inorganic materials 0.000 claims description 2
239000002184 metal Substances 0.000 claims description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
239000004615 ingredient Substances 0.000 claims 1
229910052791 calcium Inorganic materials 0.000 abstract description 5
229910052749 magnesium Inorganic materials 0.000 abstract description 2
229910052708 sodium Inorganic materials 0.000 abstract description 2
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical group CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 6
229960004308 acetylcysteine Drugs 0.000 description 6
208000028867 ischemia Diseases 0.000 description 6
230000002107 myocardial effect Effects 0.000 description 6
238000002054 transplantation Methods 0.000 description 6
239000000126 substance Substances 0.000 description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
239000003963 antioxidant agent Substances 0.000 description 4
235000006708 antioxidants Nutrition 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
230000003078 antioxidant effect Effects 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000000747 cardiac effect Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000002265 prevention Effects 0.000 description 3
239000011734 sodium Substances 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
102000003992 Peroxidases Human genes 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
102000019197 Superoxide Dismutase Human genes 0.000 description 2
108010012715 Superoxide dismutase Proteins 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
230000006870 function Effects 0.000 description 2
230000002631 hypothermal effect Effects 0.000 description 2
238000002513 implantation Methods 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
238000000034 method Methods 0.000 description 2
210000004165 myocardium Anatomy 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000002516 radical scavenger Substances 0.000 description 2
238000011084 recovery Methods 0.000 description 2
GZFOMNDCXQBAAX-BQBZGAKWSA-N (2s)-2-amino-5-[[(2r)-1-[(2-methoxy-2-oxoethyl)amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound COC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O GZFOMNDCXQBAAX-BQBZGAKWSA-N 0.000 description 1
241000282465 Canis Species 0.000 description 1
102000016938 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
101100366137 Mesembryanthemum crystallinum SODCC.1 gene Proteins 0.000 description 1
101100096142 Panax ginseng SODCC gene Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
241001122767 Theaceae Species 0.000 description 1
GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
229960003459 allopurinol Drugs 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000001964 calcium overload Effects 0.000 description 1
239000008148 cardioplegic solution Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
229940105657 catalase Drugs 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
239000002131 composite material Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
-1 glutathione Chemical class 0.000 description 1
230000004217 heart function Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
239000002357 osmotic agent Substances 0.000 description 1
238000010525 oxidative degradation reaction Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940072417 peroxidase Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
101150017120 sod gene Proteins 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
150000003573 thiols Chemical group 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Dentistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Environmental Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

CA002106249A 1992-09-18 1993-09-15 Solution pour la perfusion, la conservation et la reperfusion d'organes Expired - Lifetime CA2106249C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US94607392A	1992-09-18	1992-09-18
US07/946,073		1992-09-18

Publications (2)

Publication Number	Publication Date
CA2106249A1 CA2106249A1 (fr)	1994-03-19
CA2106249C true CA2106249C (fr)	2009-04-14

Family

ID=25483919

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002106249A Expired - Lifetime CA2106249C (fr)	1992-09-18	1993-09-15	Solution pour la perfusion, la conservation et la reperfusion d'organes

Country Status (9)

Country	Link
AT (1)	AT407216B (de)
BE (1)	BE1007500A3 (de)
CA (1)	CA2106249C (de)
CH (1)	CH686870A5 (de)
DE (1)	DE4331711C2 (de)
ES (1)	ES2070089B1 (de)
FR (1)	FR2695827B1 (de)
GB (1)	GB2270614B (de)
IT (1)	IT1272638B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19527734A1 (de) *	1995-07-28	1997-01-30	Hubert Verhaag	Verfahren und Vorrichtung zur Konservierung von Geweben und Organen, insbesondere von Transplantationsgeweben und -organen
US5880098A (en) *	1996-04-12	1999-03-09	Pharmacia & Upjohn Aktiebolag	Therapeutic treatment
SE9601396D0 (sv) *	1996-04-12	1996-04-12	Dieter Haeussinger	New therapeutic treatment 2
DE19706111C2 (de) *	1997-02-17	1999-02-18	Fresenius Medical Care De Gmbh	Lösung zur Aufbewahrung von Organen
RU2140152C1 (ru) *	1997-03-13	1999-10-27	Иван Антонович Мазур	Консервирующий раствор "б-2" для трансплантатов
US5834178C1 (en) *	1997-07-09	2002-04-23	Univ Wayne State	Flush-storage solution for donor organs
CN1057192C (zh) *	1997-09-10	2000-10-11	上海长征医院	一种配制多器官保存液的方法
DE19834087C1 (de) *	1998-07-29	2000-03-30	Mirzaie Sedaposhteh Massoud	Wäßrige Konservierungslösung und Verfahren zur Aufbewahrung tierischen Gewebes
FR2785501B1 (fr) *	1998-11-10	2001-01-05	Centre Nat Rech Scient	Solution de perfusion et/ou de conservation et/ou de reperfusion lors de la transplantation d'organes
GB0028414D0 (en)	2000-11-22	2001-01-03	Univ Leeds	Flush preservation solution
US20060078872A1 (en) *	2004-10-12	2006-04-13	Atsushi Taguchi	Cell-preservation liquid
WO2007128866A2 (en) *	2006-05-09	2007-11-15	Novobion Oy	Novel chemical compositions
CA2910189A1 (en) *	2013-04-24	2014-10-30	Somahlution, Llc	Organ and tissue preservation solutions having increased oxygen-content, stability and shelf life
JP2016520580A (ja) *	2013-04-29	2016-07-14	ソマールション・エルエルシー	臓器及び組織の保存溶液の酸素含量、安定性、及び貯蔵寿命を増大させるための、ポリ（０−２−ヒドロキシエチル）デンプンを含有する製剤
CN105916374B (zh)	2013-11-22	2021-11-05	索玛解有限公司	用于增加器官和组织保存溶液的稳定性和储存寿命的溶液
CN115720893B (zh) *	2022-08-08	2024-02-23	四川大学华西医院	一种甲状旁腺体外保存液和保存方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4879283A (en) *	1985-10-03	1989-11-07	Wisconsin Alumni Research Foundation	Solution for the preservation of organs
US4798824A (en) *	1985-10-03	1989-01-17	Wisconsin Alumni Research Foundation	Perfusate for the preservation of organs
ES2007994A6 (es) *	1988-08-16	1989-07-01	Grino Boira Jose Maria	Medio liquido para perfusion y preservacion de organos.
US4920044A (en) *	1988-11-08	1990-04-24	The Cleveland Clinic Foundation	Intracellular flush solution for preserving organs
US4938961A (en) *	1989-04-28	1990-07-03	Geoffrey Collins	Organ preservation solution containing pokyethylene gycol and method of performing cardioplegia
US5104787A (en) *	1990-03-05	1992-04-14	Lindstrom Richard L	Method for apparatus for a defined serumfree medical solution useful for corneal preservation
US5145771A (en) *	1990-04-12	1992-09-08	The University Of North Carolina At Chapel Hill	Rinse solution for organs and tissues
GB9021325D0 (en) *	1990-10-01	1990-11-14	Geistlich Soehne Ag	Chemical composition
CH683485A5 (fr) *	1990-11-20	1994-03-31	Pasteur Merieux Serums Vacc	Solutions de perfusion, de conservation et de reperfusion d'organes.

1993
- 1993-09-14 CH CH02760/93A patent/CH686870A5/fr not_active IP Right Cessation
- 1993-09-14 FR FR9310926A patent/FR2695827B1/fr not_active Expired - Lifetime
- 1993-09-14 BE BE9300965A patent/BE1007500A3/fr not_active IP Right Cessation
- 1993-09-15 CA CA002106249A patent/CA2106249C/fr not_active Expired - Lifetime
- 1993-09-16 IT ITMI931994A patent/IT1272638B/it active IP Right Grant
- 1993-09-17 ES ES09301971A patent/ES2070089B1/es not_active Expired - Fee Related
- 1993-09-17 GB GB9319264A patent/GB2270614B/en not_active Expired - Lifetime
- 1993-09-17 DE DE4331711A patent/DE4331711C2/de not_active Expired - Lifetime
- 1993-09-20 AT AT0189793A patent/AT407216B/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
ITMI931994A1 (it)	1995-03-16
ES2070089A1 (es)	1995-05-16
FR2695827A1 (fr)	1994-03-25
DE4331711A1 (de)	1994-03-24
ITMI931994A0 (it)	1993-09-16
GB2270614B (en)	1996-03-20
CA2106249A1 (fr)	1994-03-19
GB9319264D0 (en)	1993-11-03
GB2270614A (en)	1994-03-23
ATA189793A (de)	2000-06-15
IT1272638B (it)	1997-06-26
DE4331711C2 (de)	2001-05-03
BE1007500A3 (fr)	1995-07-18
ES2070089B1 (es)	1995-12-16
CH686870A5 (fr)	1996-07-31
FR2695827B1 (fr)	1995-07-28
AT407216B (de)	2001-01-25

Legal Events

Date	Code	Title	Description
2000-05-23	EEER	Examination request

Publication	Publication Date	Title
CA2106249C (fr)	2009-04-14	Solution pour la perfusion, la conservation et la reperfusion d'organes
US5498427A (en)	1996-03-12	Solutions for the perfusion, preservation and reperfusion of organs
Southard	1999	Organ preservation
Rabl et al.	1993	A multivitamin infusion prevents lipid peroxidation and improves transplantation performance
FR3038324A1 (fr)	2017-01-06	Procede de cryoconservation de cellules a visee therapeutique
US6054261A (en)	2000-04-25	Coenzyme Q10 compositions for organ protection during perfusion
BE1006834A3 (fr)	1995-01-03	Solution de perfusion, de conservation et de reperfusion d'organes.
US5395851A (en)	1995-03-07	Tree wound coating composition
EP1997374B1 (de)	2016-11-02	Spül- und Konservierungsverfahren eines zu transplantierenden Organs und Lösung, die bei diesem Verfahren verwendet wird
CN112167243B (zh)	2023-03-10	红细胞冻存液及快速冻存方法
CA2986267A1 (fr)	2017-03-16	Milieu de conservation injectable pour la conservation de cellules du sang placentaire, de la moelle osseuse et du sang peripherique
WO2019102172A1 (fr)	2019-05-31	Procédé de cryoconservation de cellules à visée thérapeutique
Sangappa et al.	2014	Extra-alveolar storage media for teeth: A literature review
Vara et al.	1995	Beneficial effect of S-adenosylmethionine during both cold storage and cryopreservation of isolated hepatocytes
EP2536272A1 (de)	2012-12-26	Flüssige formulierung mit aufgelösten gasen zur konservierung eines biologischen materials
FR2632820A1 (fr)	1989-12-22	Procede de conservation a basse temperature du sperme
FR2642966A1 (fr)	1990-08-17	Composition pour application capillaire
RU2049391C1 (ru)	1995-12-10	Средство для криоконсервирования костного мозга
FR3080002A1 (fr)	2019-10-18	Procede de suivi de la viabilite d'un greffon
WO2012164321A1 (en)	2012-12-06	Organ and tissue transplantation solution containing bmp-7
Claesson et al.	1991	Chlorpromazine, quinacrine, and verapamil as donor pretreatment in liver preservation, tested in the isolated perfused rat liver
FR2679107A1 (fr)	1993-01-22	Solutions de perfusion, de conservation et de reperfusion d'organes.
Wicomb et al.	1987	Loss of myocardial viability following hypothermic perfusion storage from contaminating trace elements in the perfusate
FR2669189A1 (fr)	1992-05-22	Solutions de perfusion et de stockage pour transplantations cardiaques.
FR3038325A1 (fr)	2017-01-06	Procede de cryoconservation de cellules a visee therapeutique